Company Insights

COCP supplier relationships

Explore interactive graphBrowse insights index
COCP supplier relationship map

Cocrystal Pharma (COCP) — supplier and advisor map investors need to price execution risk

Cocrystal Pharma develops oral antiviral candidates and monetizes through clinical-stage value creation: progressing molecules (notably CDI‑988) through clinical trials to generate licensing or partnership revenues and milestone payments, while funding operations through equity raises and registered direct offerings. The company's operating model is development‑heavy, dependent on third‑party CROs/CMOs and placement agents to underwrite financing, which drives supplier concentration and execution risk. For a quick vendor risk scorecard and detailed relationship feed, visit https://nullexposure.com/.

Why supplier relationships matter for COCP’s valuation

Cocrystal is a capital‑intensive biotech with limited revenue (roughly $0.5M trailing twelve months) and a small market capitalization (about $14.9M), so supplier counterparty strength and funding channels directly determine clinical progress and dilution. The public record shows two financing events coordinated by the same placement agent, an active human challenge study partner at Emory, and recurring investor relations and conference engagements — together those link operational execution to short-term liquidity and long‑term partnership optionality.

Key operating signals: the company contracts CROs and CMOs for chemistry, preclinical work, and clinical trials; it has engaged a CRO (hVIVO/Open Orphan) with a multi‑million dollar study budget; it relies on placement agents for at‑the‑market registered direct offerings; and lease extensions indicate a committed headquarters footprint. These are company‑level characteristics investors should embed in models.

Counterparty catalog — what every relationship does and why it matters

H.C. Wainwright & Co.

H.C. Wainwright acts as Cocrystal’s exclusive placement agent on multiple registered direct/ATM offerings in fiscal 2025, including an engagement around an up‑to‑$13 million program and a subsequent closing of $4.7 million with additional potential from warrants. According to GlobeNewswire releases in September and November 2025, H.C. Wainwright executed and closed placement transactions that provided near‑term liquidity for the company.

Zacks SCR

Zacks SCR has provided research coverage and disclosed it received compensation from the issuer or associated IR firms, representing a paid coverage relationship that supports visibility to investors. This disclosure appeared with a March 2026 post on Yahoo Finance noting the compensated research arrangement.

Alliance Advisors IR

Alliance Advisors IR is listed repeatedly as Cocrystal’s investor relations contact, coordinating press distribution for financial results and offering closings, which centralizes external communications and investor engagement. Several press releases and QuiverQuant distributions in late 2025 and early 2026 identify Alliance Advisors IR and Jody Cain as investor contacts for the company.

Alliance Advisors

Separately shown as an investor relations reference in the September 2025 offering announcement, Alliance Advisors is tied to Cocrystal’s public investor communications and outreach during the registered direct offering period. The September 12, 2025 GlobeNewswire release lists Alliance Advisors contact information for investor inquiries.

GlobeNewswire

GlobeNewswire is the primary distributor for Cocrystal’s press releases covering financings, quarterly results, and conference appearances; some distributed releases were also flagged as being summarized by third‑party services. QuiverQuant and AI‑summary notes in November 2025 and other postings indicate GlobeNewswire distributed both original releases and summaries used by downstream aggregators.

Noble Capital Markets, Inc.

Noble Capital Markets hosted Cocrystal at an emerging growth conference in December 2025 and provided promotional access to investors, indicating the company leverages small‑cap conferences to maintain market visibility for fundraising and analyst outreach. The December 1, 2025 GlobeNewswire release details the conference participation and the company’s discounted registration offer for guests.

Emory University School of Medicine

Emory is Cocrystal’s clinical trial partner for a Phase 1b human challenge study evaluating CDI‑988; the Emory IRB approval and subsequent study activity are core to near‑term clinical readouts. Stocktitan and GlobeNewswire posts from November 2025 report IRB approval and that the norovirus challenge study is underway at Emory.

(Each relationship summary above is drawn from public press releases and market postings between September 2025 and March 2026.)

Operational constraints that shape supplier exposure

  • Reliance on third‑party manufacturers: The company explicitly notes it will rely on external manufacturers for preclinical, clinical and potential commercial supplies, creating supply‑chain and quality control dependence that is typical for small biotech but material to commercialization timelines.
  • CRO/CMO and service provider use with multi‑million budgets: The company documented a study agreement with a CRO (hVIVO, a subsidiary of Open Orphan plc) that included a reservation fee of $1.7M and a total study budget of approximately $6.8M, signaling single‑study supplier spend in the $1M–$10M band and concentrated project risk.
  • Active contractual posture and facility commitments: Recent lease extensions and expansions (multi‑year terms) indicate an active operational footprint and ongoing fixed costs, which affect near‑term cash burn and supplier payment priority.

The hVIVO/Open Orphan engagement is an explicit service‑provider relationship named in company disclosures; the manufacturer reliance and spend band are company‑level signals investors must factor into scenario analyses.

For a consolidated risk and supplier scoring framework tailored to small biotech issuers like Cocrystal, go to https://nullexposure.com/.

How investors and operators should model these relationships

  • Stress financing channels: Model recurring at‑the‑market or registered direct offerings executed through a single placement agent and include dilution scenarios tied to additional tranches or warrant exercises; H.C. Wainwright’s September–November 2025 activity is a template for future capital raises.
  • Model single‑study concentration: Treat the Emory‑led human challenge study and the hVIVO engagement as binary execution nodes with milestone‑linked spend (~$6.8M) and potential readout value; a failed or delayed study would directly impact near‑term valuation and cash runway.
  • Prioritize supplier continuity planning: Include contingency assumptions for transferring manufacturing or CRO tasks, and quantify switching costs and regulatory lag given reliance on external CMOs and CROs.

Key modeling assumptions to lock in: cash runway under current burn and recent $4.7M close, probability‑weighted study outcomes for CDI‑988, and dilution sensitivity to an additional up‑to‑$13M registered direct program.

Bottom line and next steps

Cocrystal’s progress is tightly coupled to a small set of counterparties: placement agents for financing, a clinical partner (Emory) for a pivotal human challenge study, and CRO/CMO providers for study execution. This concentration creates asymmetric upside on positive clinical news and asymmetric downside on execution or funding interruptions. For investors focused on supplier risk and funding pathways, the public record through late 2025 and early 2026 gives a clear mapping of those dependencies.

Explore an extended supplier risk profile and counterparty scoring for COCP at https://nullexposure.com/ to convert this relationship map into actionable exposure limits and scenario tests.